Biosyent Inc. (RX) Insider Rene Christopher Goehrum Sells 36,000 Shares

Biosyent Inc. (CVE:RX) insider Rene Christopher Goehrum sold 36,000 shares of the business’s stock in a transaction that occurred on Wednesday, September 12th. The shares were sold at an average price of C$9.60, for a total value of C$345,600.00.

Rene Christopher Goehrum also recently made the following trade(s):

  • On Friday, September 7th, Rene Christopher Goehrum sold 17,700 shares of Biosyent stock. The shares were sold at an average price of C$9.55, for a total value of C$169,035.00.
  • On Monday, September 10th, Rene Christopher Goehrum sold 40,852 shares of Biosyent stock. The shares were sold at an average price of C$9.60, for a total value of C$392,179.20.

Shares of RX opened at C$9.50 on Friday. Biosyent Inc. has a 52-week low of C$8.00 and a 52-week high of C$11.00.

Biosyent Company Profile

BioSyent Inc, a specialty pharmaceutical company, acquires or in-licenses, develops, and sells various pharmaceutical and other healthcare products in Canada and internationally. The company's products include FeraMAX 150, an oral hematinic for the treatment of iron deficiency anaemia; FeraMAX Powder, a water soluble oral iron supplement, which helps the body form red blood cells; RepaGyn, a vaginal suppository for the healing of the vaginal mucosa, as well as for the treatment of vaginal dryness caused by menopause, stress, and chemotherapy; Proktis-M, a rectal suppository designed to help healing of the anus and rectum; Aguettant System for pre-filled syringes that are used for various injectable medications in hospital and acute care settings; and Cysview for the detection and management of non-muscle invasive papillary bladder cancer.

Further Reading: What does the Dow Jones Industrial Average (DJIA) measure?

Insider Buying and Selling by Quarter for Biosyent (CVE:RX)

Receive News & Ratings for Biosyent Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Biosyent and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply